Technology | Interventional Radiology | August 16, 2019

Profound Medical Receives U.S. FDA 510(k) Clearance for Tulsa-Pro

U.S. commercial launch of transurethral prostate tissue ablation system combining MRI and ultrasound expected in the fourth quarter of 2019

Profound Medical Receives U.S. FDA 510(k) Clearance for Tulsa-Pro

August 16, 2019 — Profound Medical Corp. announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market Tulsa-Pro for ablation of prostate tissue.

Tulsa-Pro is a transurethral prostate tissue ablation system that combines real-time magnetic resonance imaging (MRI) with robotically-driven directional thermal ultrasound and closed-loop temperature feedback control software to deliver predictable physician prescribed ablation of whole-gland or partial prostate tissue. The Tulsa-Pro system is designed to provide customizable and predictable, incision-free and radiation-free prostate ablation while actively protecting the urethra and rectum with water cooling to preserve men’s functional abilities.

The FDA’s clearance of Tulsa-Pro was based on the company’s TACT pivotal clinical trial, which met all of its primary and secondary efficacy and safety endpoints. TACT enrolled 115 patients across the United States, Canada and Europe with biopsy-proven, organ-confined prostate cancer (67 percent and 33 percent of subjects had NCCN intermediate- and low-risk disease, respectively). All patients received primary treatment of whole-gland prostate ablation with sparing of the urethra and urinary sphincter. TACT demonstrated that the Tulsa-Pro provides safe and effective prostate tissue ablation, with minimal adverse events, significant prostate volume and prostate specific antigen (PSA) reduction, and low rates of residual prostate disease. The favorable safety profile offered by the Tulsa-Pro contrasts with radical prostatectomy and radiation therapy that can leave many men with permanent erectile dysfunction, urinary incontinence and bowel dysfunction. The TACT study also demonstrated a favorable risk-benefit profile in the context of other ablative approaches, including whole-gland high intensity focused ultrasound (HIFU) and cryotherapy.

The FDA label for Tulsa-Pro will allow U.S. surgeons to perform prostate tissue ablation procedures indiscriminate of tissue type, including malignant and benign.

“We are pleased with the FDA’s expeditious review of our application,” said Arun Menawat, Profound’s CEO. “We believe this, combined with the label that the Agency approved for TULSA-PRO®, serves as a testament to our technology’s strong clinical profile.”

Profound Medical CEO Arun Menawat said the company is preparing for the U.S. commercial launch of Tulsa-Pro in the fourth quarter of 2019. 

For more information: www.profoundmedical.com

Related Content

Profound Medical Corp. Announces First Paid Procedure Using TULSA-PRO System

Profound Medical Corp. and Philips Announce First TULSA-PRO Sale in Finland

Related Content

Samsung to highlight its medical imaging portfolio with its latest radiology innovations in ultrasound, digital radiography and mobile computed tomography
News | Radiology Imaging | December 02, 2020
December 2, 2020 — Samsung Electronics Co., Ltd.
For men with early-stage prostate cancer, choices about initial treatment carry varying risks of "financial toxicity," reports a study in The Journal of Urology, Official Journal of the American Urological Association (AUA). The journal is published in the Lippincott portfolio by Wolters Kluwer.

Getty Images

News | Prostate Cancer | December 02, 2020
December 2, 2020 — ...
The GE Healthcare Allia IGS 7 angiography system. #RSNA #RSNA20 #RSNA2020

The GE Healthcare Allia IGS 7 angiography system.

News | Angiography | December 01, 2020
December 3, 2020 — GE Healthcare is introducing a new, smaller and lighter weight robotic driven ...
By eliminating the need to move neonates from the NICU to the radiology department, Aspect Imaging’s Embrace enables a safer way to perform the MRI procedure
News | Magnetic Resonance Imaging (MRI) | December 01, 2020
December 1, 2020 — Based on its recent analysis of the global neonatal intensive care unit magnetic resonance imaging
Resoundant Inc., announced hat it has entered into a strategic partnership with United Imaging Healthcare to begin offering advanced magnetic resonance elastography (MRE) on leading United Imaging MRI systems.
News | Magnetic Resonance Imaging (MRI) | November 30, 2020
November 30, 2020 — Resoundant Inc., announced that it has entered into a strategic partnership with...
Chest CT images in a 34-year-old man with fever for 4 days. Positive result of reverse-transcription polymerase chain reaction assay for severe acute respiratory syndrome coronavirus 2 using a swab sample was obtained on February 8, 2020. Dates of examination are shown on images. A, Chest CT scan with magnification of lesions in coronal and sagittal planes shows a nodule with reversed halo sign in left lower lobe (box) at the early stage of the pneumonia. B, Chest CT scans in different axial planes and coro

Chest CT images in a 34-year-old man with fever for 4 days. Positive result of reverse-transcription polymerase chain reaction assay for severe acute respiratory syndrome coronavirus 2 using a swab sample was obtained on February 8, 2020. Dates of examination are shown on images. A, Chest CT scan with magnification of lesions in coronal and sagittal planes shows a nodule with reversed halo sign in left lower lobe (box) at the early stage of the pneumonia. B, Chest CT scans in different axial planes and coronal reconstruction show bilateral multifocal ground-glass opacities. The nodular opacity resolved.

News | Coronavirus (COVID-19) | November 29, 2020
November 29, 2020 — The Radiological Society of North America (...